| 股票 | 申万二级 | PE | 前瞻PE | PEG | PB | 股息率 | 分红率 | 毛利率 | 固定资产 | 债/EBITDA | FCF/市值 | 营收3年 | 去年 | YTD | 近一年 | 回撤 | 波动 | 市值亿 ▾ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 康龙化成 300759 | 医疗服务 | 44.2 | 37.6 | 1.39 | 4.63 | 0.5% | 21% | 36% | 41% | 1.9 | 0.0% | +11% | +12% | +46% | +30% | -40% | 48% | 757 |
| 凯莱英 002821 | 医疗服务 | 56.8 | 42.1 | 1.45 | 3.31 | 0.8% | 41% | 44% | 32% | 0.2 | -0.2% | -13% | +24% | +78% | +49% | -25% | 54% | 588 |
| 昭衍新药 603127 | 医疗服务 | 32.7 | 51.1 | — | 3.59 | 0.3% | 30% | 43% | 10% | 0.3 | 0.9% | -10% | +112% | +23% | +31% | -38% | 66% | 322 |
| 九洲药业 603456 | 医疗服务 | 22.5 | 16.2 | 1.25 | 1.49 | 2.0% | 86% | 35% | 40% | 0.0 | 7.0% | +0% | +36% | -15% | -19% | -44% | 43% | 133 |
| 成都先导 688222 | 医疗服务 | 89.9 | 90.3 | 3.11 | 8.26 | 0.4% | 48% | 49% | 23% | 1.3 | 0.3% | +17% | +92% | +35% | +33% | -43% | 65% | 126 |
| 药康生物 688046 | 医疗服务 | 69.0 | 63.1 | 2.34 | 5.56 | 0.7% | 71% | 68% | 21% | 0.8 | 1.8% | +15% | +21% | +102% | +65% | -34% | 63% | 126 |
| 益诺思 688710 | 医疗服务 | 471.2 | 85.2 | 0.83 | 4.75 | — | 25% | 38% | 21% | 1.1 | 1.9% | -2% | +26% | +80% | +89% | -31% | 72% | 112 |
| 药石科技 300725 | 医疗服务 | 47.4 | 41.3 | 1.21 | 2.19 | 0.9% | 31% | 42% | 32% | 0.3 | 1.4% | +7% | +16% | +12% | -8% | -34% | 48% | 100 |
| 诺思格 301333 | 医疗服务 | 45.1 | 35.6 | 2.23 | 2.71 | 0.3% | 11% | 37% | 1% | 0.3 | 0.8% | +10% | +20% | -5% | +1% | -51% | 63% | 54 |
| 普蕊斯 301257 | 医疗服务 | 52.2 | 21.9 | 1.15 | 2.40 | 0.4% | 11% | 26% | 1% | 0.0 | 0.1% | +13% | +94% | -26% | -1% | -55% | 69% | 30 |
点表头排序。市值单位亿元;去年/YTD 为前复权涨幅;债/EBITDA = 有息负债 ÷ EBITDA。